questionText: To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential impact of the decision by the National Institute for Health and Care Excellence to not recommend trastuzumab deruxtecan for HER2-low secondary breast cancer for use on NHS on the life expectancy of eligible women.
answerText: The National Institute for Health and Care Excellence (NICE) has not yet published final guidance on the use of trastuzumab deruxtecan (Enhertu) for the treatment of metastatic HER2-low breast cancer. The NICE published final draft guidance on 5 March 202...
heading: Trastuzumab Deruxtecan